BlueRock Therapeutics, a cell therapy company under Bayer, has recently announced FDA clearance for its Investigational New Drug (IND) application for OpCT-001. This investigational induced pluripotent stem cell (iPSC)-derived therapy aims to treat primary photoreceptor diseases, which are a
NImmune Biopharma has recently announced a strategic partnership with BioTherapeutics aimed at accelerating the development of precision medicines for inflammation and immunology. The collaboration is designed to bolster NImmune’s capabilities by integrating BioTherapeutics’ extensive preclinical se
Amid significant strategic shifts and infrastructural investments, KBI Biopharma has decided to discontinue mammalian drug substance manufacturing at its Geneva, Switzerland facility. This move comes following a period of substantial upgrades and expansion, signaling a concerted effort to
In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
In an industry perpetually teetering on the edge of innovation and regulation, recent events in the biopharmaceutical sector underscore the volatile yet progressive nature of biotech and pharma companies. From advancements in specific treatments to significant executive shifts, the landscape seems
In a significant development for the pneumococcal vaccine market, Vaxcyte has announced promising results from its Phase 1/2 trials, unveiling a vaccine that has the potential to challenge established leaders like Pfizer's Prevnar 20. The initial data not only showcases impressive efficacy but
Recursion Pharmaceuticals has reached a significant milestone in its journey to develop a treatment for cerebral cavernous malformation (CCM), a complex neurovascular condition. The company's leading experimental drug, REC-994, recently concluded a Phase 2 clinical trial, and the results are
In a strategic move to enhance its offerings in the biopharmaceutical sector, BioPhorum has announced the acquisition of Brookwood Global, a renowned UK-based training and educational content provider specializing in clinical research and drug safety. For over 15 years, BioPhorum has been a key
Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5%
The acquisition of a 30.5% stake in Tanvex Biopharma by Bora Pharmaceuticals is a pivotal development in the biotech sector. As the largest single corporate shareholder in Tanvex, Bora aims to leverage this strategic partnership to enhance its competitive edge in the global biopharmaceutical
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy